## **CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form**

#### The CONSORT-EHEALTH

checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*. In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED)

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

\* Required

#### Your name \*

First Last

Mary Greaney

Primary Affiliation (short), City, Country \*

University of Toronto, Toronto, Canada

Dana-Farber Cancer Ins

Your e-mail address \*

abc@gmail.com
mary_greaney@dfci.har
Title of your manuscript * Provide the (draft) title of your manuscript.
Use of Email and Telephone Prompts to Increase Self-Monitoring in a Web-Based Intervention
Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)
onot submitted yet - in early draft status
onot submitted yet - in late draft status, just before submission
<ul> <li>submitted to a journal but not reviewed yet</li> </ul>
<ul> <li>submitted to a journal and after receiving initial reviewer comments</li> </ul>
<ul> <li>submitted to a journal and accepted, but not published yet</li> </ul>
<ul><li>published</li></ul>
Other:
Journal *  If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")  onot submitted yet / unclear where I will submit this  Journal of Medical Internet Research (JMIR)  Other:
Manuscript tracking number *  If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)  on ms number (yet) / not (yet) submitted to / published in JMIR  other: 1981

**TITLE AND ABSTRACT** 

2 of 39

## 1a) TITLE: Identification as a randomized trial in the title 1a) Does your paper address CONSORT item 1a? \* I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other") yes Other: No, we did not include ra 1a-i) Identify the mode of delivery in the title Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms. 2 3 subitem not at all important O O O essential Does your paper address subitem 1a-i? \* Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Use of Email and Telephone Prompts to Increase Self-monitoring"

#### 1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

#### Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### "Telephone

Prompts" is included in the title. The title does not include the self-monitoring reports that both prompting conditions received at the end of week 2 and week 3. These reports are not included, as both prompting conditions received them.

#### 1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

#### Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Nο,

we do not include this information in the title, as the intervention did not target a primary condition or group. The intervention was available to patients 18+ years of age attending a primary care appointment.

## 1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

## 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

#### Does your paper address subitem 1b-i? \*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional

information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### "Participants

who did not meet the threshold during week 1 were randomized to one of 2 prompting conditions: Automated Assistance (AA, n=36) or Automated Assistance + Calls (AAC, n=50). During the prompting period (weeks 2 and 3), participants in the AA and AAC conditions received daily automated emails that encouraged tracking and two tailored self-monitoring reports (end of week 2, end of week 3) that provided feedback on tracking frequency; individuals in the AAC condition also received two technical

#### 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	•	0	essentia

#### Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### 'During

the prompting period (weeks 2 and 3), participants in the AA and AAC conditions received daily automated emails that encouraged tracking and two tailored self-monitoring reports (end of week 2, end of week 3) that provided feedback on tracking frequency; individuals in the AAC condition also received two technical assistance calls from trained study staff."

### 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### **Participants**

were recruited in-person. "Participants (n=100) were recruited and enrolled in a web-based intervention during a primary care well visit at an urban primary care health center"

Information is included in the abstract indicating that self-monitoring was tracked online. "and the frequency of daily self-monitoring was tracked on the study website.

#### 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



#### Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Our study examined self-monitoring rates of participants (n=100) enrolled in the study. In the methods section of the abstract, we provide the sample size for each group and report the self-monitoring rates for each group in the results section.

"Over the 16 weeks of observation, there was a significant between-group difference in the percentage that met the self-monitoring threshold each week, with better maintenance in the AAC condition than in AA (P

#### 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



#### Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Prompting can increase self-monitoring rates. The decrease in self-monitoring

after the promoting period suggests that additional reminder prompts would be useful. The use of technical assistance calls appeared to have a greater effect in promoting self-monitoring at a therapeutic threshold than email reminders alone."

#### INTRODUCTION

## 2a) In INTRODUCTION: Scientific background and explanation of rationale

#### 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We do, and the information is as follows:
"a major challenge has been initiating and maintaining use of self-monitoring tools."
"However, the use of self-monitoring tools has been suboptimal. For example, in a web-based worksite behavior change intervention, only 11%

#### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropriate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The purpose of this study is to determine the effect of a prompting intervention on self-monitoring rates. The comparator group consisted of people who self-monitored at least one behavior 3+ times during week 1. This comparator group did not receive prompts, and allowed us to determine if the prompting intervention increased self-monitoring rates to equal or greater than that of a group of individuals motivated to track at the start of the study.

#### 2b) In INTRODUCTION: Specific objectives or hypotheses

#### Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Thus, the purpose of this study is to examine the feasibility of implementing a prompting intervention in a web-based health promotion intervention."

#### **METHODS**

## 3a) Description of trial design (such as parallel, factorial) including allocation ratio

#### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We do not provide this information, as the study is a feasibility study.

# 3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons Does your paper address CONSORT subitem 3b? \* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study We did not change the study methods once the study began. 3b-i) Bug fixes, Downtimes, Content Changes Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

During weeks 1-17, we did not have any staff turnover or problems with the yeb site.

#### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

For both the parent study and the sub-study that is the focus of this manuscript "Enrollment eligibility included: being a health center patient, being 18+ years of age, having a scheduled well visit or chronic disease management appointment, and being able to read English. Patients were ineligible if they had undergone cancer treatment in the previous year and/or had a diagnosis of dementia, blindness, neurodegenerative and/or psychiatric illness (including substance abuse, psychosis, schizophrenia in the previous five years)."

#### 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We did not assess computer literacy as an eligibility requirement, but participants were required to have an email address and the ability to access the internet daily.

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Recruitment: Recruitment was brief and study staff did not get to know the participant, although they met briefly.

"Recruitment for both the parent study and the sub-study was the same. Eligible patients were sent an introductory letter that outlined the study, and let them know that they may be approached and invited to join the study at their upcoming appointment. At check in, study staff met the patient and verbally introduced the study and interested individuals

#### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.



#### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We state that participants were made aware of the study via a mailed letter, and that potential participants were approached by study staff at a scheduled appointment.

"At check in, study staff met the patient and verbally introduced the study and interested individuals provided written informed consent and completed a self-administered baseline survey.".

#### 4b) Settings and locations where the data were collected

#### Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We include the following information:

"The prompting study (here-on-in referred to as 'sub-study') described in this paper was a sub-study study of Healthy Directions 2 (HD2), a randomized controlled trial of a multiple risk factor cancer prevention intervention conducted in two urban primary care health centers located in metropolitan Boston."

#### 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 4b-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

ıbl	icatio
-----	--------

o-ii) Report how institutional affil filiations with prestigious h	iation	s are	disp	olaye	d to p	potential pa					
gards to an intervention.(N	Not a	requi			– des 5	scribe only	f this ma	y bias	s results)		
ubitem not at all important						essential					
iotem not at an important						Coochida					
le do not discuss this. Al nd the study web site inco ealthy Directions. This we	orpor	ated	a log	o de:	signe	ed specific		<b>Ξ</b> ,			
•			•	_	•						ed
eplication, includir	ng h	ow	and	d wh	nen	they we	re act	ually	y admii	nister	ed
eplication, including the plication, including the plication names, crede the plant of the plication names, credential, athors/evaluators are owner.	ng h entia affilia	OW  I, aff	and	ons one de	of the	e develop pers, spon oftware, th	re actorers, sports, and	nsors	y admin s, and overs [6] (if	nister wners	
eplication, including the plication, including the plication names, credential, athors/evaluators are owner.	ng h entia affilia	OW  I, aff	and	ons one de	of the	e develop pers, spon oftware, th	re actorers, sports, and	nsors	y admin s, and overs [6] (if	nister wners	
) The interventions eplication, including incl	entia affilia ers or ed el	I, affations	iliation of the elope mere i	ons one deer of the the	of the evelope the seman	e develop pers, spon oftware, th	re actorers, sports, and	nsors	y admin s, and overs [6] (if	nister wners	

information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The purpose of the prompting interventions were to increase use the
self-monitoring tools on the study web site. The web site was developed
at the Dana-Farber Cancer Institute, and we did not mention names,
credential, affiliations of the developers, sponsors, and owners.
·

#### 5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.



#### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, we do not discuss the development of the Healthy Directions 2 web site,

which was developed for the parent study, but usability testing of the web site was conducted.

#### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The prompting intervention consisted of emails and two self-monitoring reports. In addition, depending on randomization some participants received technical assistance calls. This intervention did not change over the course of the study. The web site that participants used for tracking was developed at the Dana-Farber Cancer Institute, and did not change, except new blog postings were added.

ndicate direct quotes from	s sul	0	0	0	0	essential
Copy and paste relevant sendicate direct quotes from						
nformation not in the ms, o Subitem 5-iv is not applica	your r brie	s fro manı	m the uscrip	mar ot), o	r elal	ript (include quotes in quotation marks "like this" to borate on this item by providing additional item is not applicable/relevant for your study
apture video, and/or pronsure replicability by publ	ovidions of the	<b>ng fl</b> o g the e alg	owch sourd orithr	narts ce co ns us	of tode, assed.	and/or providing screenshots/screen-capture video Replicability (i.e., other researchers should in
	1	2	3	4	5	
ubitem not at all important	0	0	0	0	0	essential
ndicate direct quotes from	ection your r brie rmati	s fro mand fly ex on (e	m the uscrip cplain .g., s	e mar ot), o why ourci	r elal the i ing c	
-vi) Digital preservation						ation, but as the intervention is likely to change or sure the intervention is archived (Internet Archive,
Digital preservation: Providi isappear over the course rebcitation.org, and/or pub	of the lishin	g the	sour	ce c		or screenshots/videos alongside the article). As ensider creating demo pages which are accessible

Does your paper address subitem 5-vi	Do	es yo	ur paper	address	subitem	5-vi
--------------------------------------	----	-------	----------	---------	---------	------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Ve do not discuss this in the paper, but web sites created for studies at the
Dana-Farber Cancer Institute are archived.

#### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers /readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We include the following information:

"Enrollment eligibility included: being a health center patient, being 18+ years of age, having a scheduled well visit or chronic disease management appointment, and being able to read English. Patients were ineligible if they had undergone cancer treatment in the previous year and/or had a diagnosis of dementia, blindness, neurodegenerative and/or psychiatric illness (including substance abuse, psychosis, schizophrenia

## 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to

indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We provide the following detailed information about the intervention groups and the comparator group.

"A minimum threshold of self-monitoring at least one behavior three or more times per week was set [13] and participants who met this threshold during week 1 did not receive prompts (Observation Only, OO; n=14), but were followed throughout the study as a comparison group to the two prompting conditions. Participants who did not meet the self-monitoring

#### 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.



#### Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants were encouraged to self-monitor daily.

We set a minimum threshold for self-monitoring, as described below.

" A minimum threshold of self-monitoring at least one behavior three or more times per week was set" W examined the number of weeks that participants met this threshold, although we also examined whether participants monitored 1+ times per week."

#### 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The emails were automated, and the technical assistance calls were conducted by study staff."

#### 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 5-xi? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The purpose of the paper was to examine the use of prompts, and these

described as follows.

"Email messages changed daily, and included a brief message about the benefits of self-monitoring and a hyperlink to the study website. Participants could choose to respond directly to the email with their tracking information instead of logging into the website; emailed

#### 5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This was a sub-study of Healthy Direction 2 (HD2). Sub-study participants received the HD2 intervention materials via the web. We describe this intervention as follows.

"The HD2 intervention targeted multiple cancer risk factors, and was designed to: (1) promote physical activity, (2) reduce red meat intake, (3) increase fruit and vegetable consumption, (4) promote daily multivitamin use, and (5) promote smoking cessation, as applicable.

1/30/2012 1:51 PM 17 of 39

## 6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

#### Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We include the following information about the outcome measures.

"Tracking measures: We created two categories of tracking measures. The first, self-monitoring measures, is focused on frequency of monitoring while the second, threshold measures, was created to examine the minimum weekly therapeutic threshold of self-monitoring three or more times per week. We used multiple measures to attempt to fully capture participants' interaction with monitoring.

## 6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

bopy and paste relevant sections from manageript text
We did not use any online questionnaires in this study.

## 6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

We examined all self-monitors and the more behaviors and the self-monitors are the self-monitors.						
						ative feedback from participants was obtained
Describe whether, how, and emails, feedback forms, inte		•				ack from participants was obtained (e.g., through
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address Copy and paste relevant sec We did not obtain feedback participants, although this w	ctions on t	s fron he pr	n ma omp	nusc ting i	nter	vention from
6b) Any changes to reasons	tria	l ou	tco	me	s at	fter the trial commenced, with
indicate direct quotes from y information not in the ms, or	ction: our i brief	s fron manu ly exp	n the scrip plain	mar ot), o why	nusc r elal the i	cript (include quotes in quotation marks "like this" to aborate on this item by providing additional item is not applicable/relevant for your study
No changes were made to t study began.	ne si	way (	outco	omes	s (se	en monitoring) after the

#### 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether an the sample size	d ho	ow e	xpec	ted a	attrit	tion was taken into account when calculating
•	expe	cted	attriti	on w	as ta	aken into account when calculating the sample size
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
Does your paper address						
indicate direct quotes from y	our	manı	uscrip	ot), o	r ela	title (include quotes in quotation marks "like this" to borate on this item by providing additional item is not applicable/relevant for your study
The study was a feasibility s participants needed to dete could be recruited within a s	ermir	ne if t	the in	terve	ntior	n was feasible, and

## 7b) When applicable, explanation of any interim analyses and stopping guidelines

#### Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We did not conduct interim analyses. We did, however, examine participants self-monitoring rates during week 1, as this information was used to determine who would be randomized to the prompting interventions.

#### 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

#### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In this study, all providers provided a study endorsement, and randomization of providers was based on the randomization pattern used in parent study.	

## 8b) Type of randomisation; details of any restriction (such as blocking and block size)

#### Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants who did not meet the self-monitoring threshold during week 1 were

randomized to one of the two prompting conditions.

"Participants who did not meet the self-monitoring threshold during week 1 were randomized based on primary care physician, following the randomization scheme of the parent study, to receive one of 2 prompting interventions: Automated Assistance (AA) or Automated Assistance + Calls

# 9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

#### Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

|--|

10) Who generated the random allocation sequence, who enrolled

#### participants, and who assigned participants to interventions

#### Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study	did not imp	lement a ra	ndom alloc	ation sequen	ice.	

# 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

#### 11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).



#### Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Health care providers did not know if their patients would or would not receive

the prompting intervention. Providers did know that their patients enrolled in the study.

Participants knew that they enrolled in a web-based intervention, but did not know that their self-monitoring rates would be used to determine randomization.

## 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

1 2 3 4 5

subitem not at all important OOOOOessential	
Does your paper address subitem 11a-ii?  Copy and paste relevant sections from the manuscript (include quotes in quota indicate direct quotes from your manuscript), or elaborate on this item by provi information not in the ms, or briefly explain why the item is not applicable/relevant	iding additional
Participants knew that they enrolled in the Healthy Direction study, but were unaware as what prompting intervention, if any they would receive. They were made aware that they might receive emails and technical assistance calls.	
11b) If relevant, description of the similarity of intervent	tions
(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)	
Does your paper address CONSORT subitem 11b? * Copy and paste relevant sections from the manuscript (include quotes in quota indicate direct quotes from your manuscript), or elaborate on this item by provi information not in the ms, or briefly explain why the item is not applicable/relevant	iding additional
Not relevant to this study.	

## 12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

#### Does your paper address CONSORT subitem 12a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Participants were recruited clustering by provider. The study was view was largely delivered outside	dy. The intervention					
intervention/comparator as ir participants who did not use	al wit ntend the a nalys atic [	th attr ded a applic sis is [4]).	rition and at catior stror	/ mis ttrition n or d ngly d	sing n is t Irop lisco	on / missing values g values: Not all participants will use the typically high in ehealth trials. Specify how ped out from the trial were treated in the statistical buraged, and simple imputation techniques such as
	1			4		
subitem not at all important	0	0	0	0	0	essential
indicate direct quotes from y	our i brief pants wee	manu fly ex s who ek, an	uscrip plain o enr	ot), or why olled ople	elal the i in th	o did not self-monitor
12b) Methods for ad adjusted analyses  Does your paper address				·		s, such as subgroup analyses and
Copy and paste relevant sec indicate direct quotes from y	ctions our i brief ces b	s fror manu fly ex petwe	m the uscrip plain een th	man ot), or why ne 3	usc ela the grou	cript (include quotes in quotation marks "like this" to aborate on this item by providing additional item is not applicable/relevant for your study ups in all tracking

## X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

subheading under "	Me	tho	ds"	] (n	ot a	CONSORT item)
X26-i) Comment on ethics	coi	nmit	tee a	ppro	oval	
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
indicate direct quotes from y	ction your	s fro manı	m the	e mar pt), o	r elal	ript (include quotes in quotation marks "like this" to borate on this item by providing additional item is not applicable/relevant for your study
"The sub-study was approve Vanguard Medical Associate		y the	Insti	tutior	nal R	eview Board at Harvard
	oce	dures prov	e.g.	, if co	onse 4a-i	nt was obtained offline or online (how? Checkbox, i). See [6] for some items to be included in informed
subitem not at all important	0	0	0	0	0	essential
indicate direct quotes from y	ction your brie form t the uals red b	s fro mani fly ex ation patie provi	m the uscrip cplair : ent ar ided line s	e mar pt), o n why nd ve writte urvey	r elal the i rbally en inf	
Safety and security procedu	ires, rm (e	incl. e.g., e	priva educ	cy co ation	and	lerations, and any steps taken to reduce the training, availability of a hotline)
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We do not address this in the paper. However, for purposes here, this is a minimal risk study. Confidentiality was maintained by numerically coding data, disguising identifying information, and by keeping all data in locked file drawers. All information obtained from subjects was accessible only to research staff.

We did not have a patient's first and last name or any private health information on the website, so loss of confidentiality did not exist for

#### **RESULTS**

# 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The

number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

#### Does your paper address CONSORT subitem 13a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We describe the number of study participants in each of the three groups earlier in the manuscript (see Methods). All individuals who enrolled in the study are included in the analyses.

## 13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional

13b-i) Attrition diagram  Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or us intervention/comparator in each group plotted over time, similar to a survival curve) or other figurables demonstrating usage/dose/engagement.  1 2 3 4 5  subitem not at all important	formation not in the ms, or b Il individuals who enrolled in								le/relev	ant for yo	our study	
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or us intervention/comparator in each group plotted over time, similar to a survival curve) or other figurables demonstrating usage/dose/engagement.  1 2 3 4 5 subitem not at all important												
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or us intervention/comparator in each group plotted over time, similar to a survival curve) or other figurables demonstrating usage/dose/engagement.  1 2 3 4 5 subitem not at all important												
Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or us ntervention/comparator in each group plotted over time, similar to a survival curve) or other figurables demonstrating usage/dose/engagement.  1 2 3 4 5 subitem not at all important												
Does your paper address subitem 13b-i? Copy and paste relevant sections from the manuscript or cite the figure number if applicable (in quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaboratem by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  We do not include an attrition diagram. The included figures (number 2 and 3) show the use and the self-monitoring rates.  Does your paper address CONSORT subitem 14a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	trongly recommended: An a tervention/comparator in ea	ch gi	roup	plot	ted c	ver						
Does your paper address subitem 13b-i? Copy and paste relevant sections from the manuscript or cite the figure number if applicable (in quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaboratem by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  We do not include an attrition diagram. The included figures (number 2 and 3) show the use and the self-monitoring rates.  14a) Dates defining the periods of recruitment and follow-up  Does your paper address CONSORT subitem 14a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	bles demonstrating usage/o											
Copy and paste relevant sections from the manuscript or cite the figure number if applicable (in quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate tem by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  We do not include an attrition diagram. The included figures (number 2 and 3) show the use and the self-monitoring rates.  14a) Dates defining the periods of recruitment and follow-up  Does your paper address CONSORT subitem 14a? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	ubitem not at all important	0	0	0	0	0	essential					
Copy and paste relevant sections from the manuscript or cite the figure number if applicable (in quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborated by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  We do not include an attrition diagram. The included figures (number 2 and 3) show the use and the self-monitoring rates.  Idaa) Dates defining the periods of recruitment and follow-up  Does your paper address CONSORT subitem 14a? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study												
S) show the use and the self-monitoring rates.  14a) Dates defining the periods of recruitment and follow-up  Does your paper address CONSORT subitem 14a? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to address direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	opy and paste relevant sect uotes in quotation marks "lik em by providing additional ir	tions e thi nform	fror s" to natio	n the	mar cate	dire	ct quotes f	rom your	manus	cript), or	elaborate	
Does your paper address CONSORT subitem 14a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	Ve do not include an attrition	ı diaç	gran			clude	ed figures	(number 2	2 and			
Does your paper address CONSORT subitem 14a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to additional providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	,											
Does your paper address CONSORT subitem 14a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to additional providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study												
Does your paper address CONSORT subitem 14a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to additional providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study												
Does your paper address CONSORT subitem 14a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to ndicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study												
Does your paper address CONSORT subitem 14a? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study												
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to ndicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	4a) Dates defining t	he	per	riod	S O	f re	ecruitme	ent and	follo	w-up		
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like to ndicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	oes vour naper address	CON	ISOI	RT s	uhite	em 1	14a? *					
We state that the participants were recruited in March of 2010.	opy and paste relevant sect dicate direct quotes from yo	tions our m	fror	n the Iscrip	mar ot), o	nusc r ela	ript (include borate on t	this item b	y prov	iding add	litional	nis" to
	Ve state that the participants	wer	re re	cruite	ed in	Mar	ch of 2010	),			·	

27 of 39 1/30/2012 1:51 PM

Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"

			_	_	_	
	1	2	3	4	5	
ubitem not at all important	0	0	0	0	0	essential
es your paper address by and paste relevant sec cate direct quotes from y rmation not in the ms, or	ction our	s fror manu	n the	man ot), or	elal	borate on t
d not include this infor	mati	ion in	the p	papei	; as	we are una
t secular trends that	tool	c plac	e du	ring t	he ti	me of the
	_	_				
o) Why the trial er	nde	d o	r Wa	as s	top	ped (ea
oes your paper address opy and paste relevant sec						
licate direct quotes from your ormation not in the ms, or	our/	manı	ıscrip	ot), or	elal	borate on t
ot applicable ,						

## 15) A table showing baseline demographic and clinical characteristics for each group

NPT: When

applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

#### Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

primary care setting.	as th	e inte	erven	tion p	orima	arily took p	ace out of	the			
15-i) Report demographics In ehealth trials it is particular such as age, education, gene participants, if known.	rly im der, :	nport socia	ant to	repo onom	ort d	emograph	s associa				
	-		3								
subitem not at all important		0	0			essential					
Does your paper address	ctions	s fror	n the	man				ı quo	otatio		e this
Copy and paste relevant sec indicate direct quotes from y information not in the ms, or We include the following info "Most participants were colle	brief orma	ily ex ition:	plain	why	the i	tem is not	pplicable/	prov relev			dy

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

#### 16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essentia

#### Does your paper address subitem 16-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

•	rere done by group assignment that was determined at Group assignment was based on use of self-monitoring
	vsis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In this manuscript, we include all people who joined the study at
baseline. If a person did not track during a week, their tracking
frequency was recorded as 0.

# 17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

#### Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We include the following information (see below).

Over the course of the observation period. The repeated measures models examining whether self-monitoring occurred each week revealed a within-group effect for time (P < .001), but not a between-group effect. The analyses examining whether the threshold was met each week revealed a within-group effect (P < .001) and a between-group effect (P = .04). The AA condition was less likely than the AAC condition to

#### 17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This

	1	2	3	4	5	
item not at all important	0	0	0	0	0	essential
ate direct quotes from y	ctions our i brief ring) ures. je: 0- ts se tinuo	s frommanumanumanumanumanumanumanumanumanuman	m the uscrip uscrip uscrip uscrip dete dete We uscrip uscr	mary mary mary then ed a	r elal the i mea ed th det det t lea icipa	e total number of ermined the total st once (range: 0-16), ints self-monitored
b) For binary outc	om		pre	ser	ntat	ion of both absolute and rel
ndicate direct quotes from y	CO ctions	<b>NSO</b> s froi mani	RT s m the	mar ot), o	<b>em 1</b> nusc r elal	<b>7b? *</b> ript (include quotes in quotation marks " porate on this item by providing addition tem is not applicable/relevant for your s

exploratory

#### Does your paper address CONSORT subitem 18?\*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

1/30/2012 1:51 PM 31 of 39

ONSORT-EHE	ALTH (V 1	61)-	Submission	/Publicatio	on Form

This does not apply to our r	nanu	scrip	t.			
18-i) Subgroup analysis o		•	_	•		
stressed that this is a self-se						uncommon in ehealth trials, but if done, it must be longer an unbiased sample from a randomized trial
(see 16-iii).	1	2	2	4	_	
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
				_		
Does your paper address Copy and paste relevant sec					nusci	ript (include quotes in quotation marks "like this" to
						borate on this item by providing additional item is not applicable/relevant for your study
This is not relevant, as the a						
study.						
19) All important ha	rms	or	uni	nte	nde	ed effects in each group
for specific guidance see C	CONS	SOR	T for	harm	ıs)	
Does your paper address Copy and paste relevant sec						<pre>19? * ript (include quotes in quotation marks "like this" to</pre>
ndicate direct quotes from y	your	manı	ıscrip	ot), o	r elal	borate on this item by providing additional
ntormation not in the ms, or We are not aware of any ha						item is not applicable/relevant for your study
participants.		o. a		aoa	01100	and any state

#### 19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects

Does your paper address Copy and paste relevant secondicate direct quotes from y information not in the ms, or We are not aware of any priving the period.	<b>sul</b> ction our brie	s fro mani fly ex	m the uscrip kplain	e mar ot), o	nusc r ela			otation marks "like t
opy and paste relevant sec dicate direct quotes from y formation not in the ms, or Ve are not aware of any priv	ction our brie	s fro mani fly ex	m the uscrip kplain	e mar ot), o	r ela			otation marks "like t
opy and paste relevant sec dicate direct quotes from y formation not in the ms, or /e are not aware of any priv	ction our brie	s fro mani fly ex	m the uscrip kplain	e mar ot), o	r ela			otation marks "like t
	vacy	/ brea	aches		tne			
,				or t	echn	ical problems o	uring the	
9-ii) Include qualitative fe	edh	nack	from	n nar	ticin	ants or obser	vations f	rom staff/researc
nclude qualitative feedback								
trengths and shortcomings		•						,
r uses. This includes (if ava	ailab	le) re	ason	s for	why	people did or o	lid not use	e the application as
ntended by the developers.								
	1	2	3	4	5			
ubitem not at all important	0	0	0	0	0	essential		
Does your paper address								
Copy and paste relevant sec								
ndicate direct quotes from y nformation not in the ms, or								
The addition of qualitative re								evant for your study
but we did not incorporate th					a ilio	e addition to the	study,	
				,-				

DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In

addition, take into account the partial blinding, and unequal each group						
with primary outcomes as	<b>nd p</b> ı d sun	roce: nmar	ss o	utco	mes	he answers suggested by the data, starting (use) rs suggested by the data, starting with primary
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
indicate direct quotes from	ction: your	s fror manu	m the	mar ot), or	elal	ript (include quotes in quotation marks "like this" to porate on this item by providing additional tem is not applicable/relevant for your study
<b>22-ii) Highlight unanswerd</b> Highlight unanswered new q	uest 1	ions,	sugg 3	gest f 4	uture 5	e research.
subitem not at all important	0	0	0	0	0	essential
indicate direct quotes from	ction: your labeled to exels of a mo	s frommanu fly ex xplore f enga re ex ater s	m the uscrip uplain e the agen uplicit self-r	e mar ot), or why natu nent ( focu monit	relal the i re of (modes on oring	dality, frequency, enhancing J."
20) Trial limitations,	ade	dres	ssin	ıg s	our	ces of potential bias, imprecision,

20-i) Typical limitations in ehealth trials

and, if relevant, multiplicity of analyses

	ies,	, incr	easir	ng ris	k for	ealth trials are rarely blinded. Ehealth trials often a Type I error. Discuss biases due to non-use of rmed consent procedures, unexpected events.
	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential
indicate direct quotes from y	ction your	s froi mani	m the uscrip	man ot), or	elal	ript (include quotes in quotation marks "like this" to corate on this item by providing additional tem is not applicable/relevant for your study
"Study limitations include a sample, which may limit ger non-prompting control group self-monitor during the first	nerali p tha	izabil t incl	ity, ar uded	nd the only	lac	k of a
21) Generalisability  NPT:  External validity of the trial fit comparators, patients, and of trial	` ndin(	gs ac	cordi	ng to	the	
21-i) Generalizability to ot		ons: I	n pa			
	T set ns		•		ral p	scuss generalizability to a general Internet atient population, including applicability of the study
population, outside of a RC	T set	2	and g	genei 4	ral pa	

21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

subitem not at all important o o essential  Does your paper address subitem 21-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  We do not discuss this, as this was a feasibility study. The next step would be to do a RCT with a larger sample size.		1	၁	2	1	5	
Does your paper address subitem 21-ii?  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study. We do not discuss this, as this was a feasibility study. The next step would be to do a RCT with a larger sample size.	cubitom not at all important						occontial
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study. We do not discuss this, as this was a feasibility study. The next step would be to do a RCT with a larger sample size.	Subitem not at all important						esserillai
OTHER INFORMATION	Copy and paste relevant se indicate direct quotes from information not in the ms, o We do not discuss this, as	ection: your r brief this v	s froi manu fly ex vas a	m the uscrip xplain ı feas	mar ot), oi why	r elal the i	aborate on this item by providing additional item is not applicable/relevant for your study
23) Registration number and name of trial registry			ır aı	nd r	nam	ne o	of trial registry
Does your paper address CONSORT subitem 23? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "ClinicalTrials.gov Identifier: NCT01415492"	Copy and paste relevant se indicate direct quotes from information not in the ms, o	ection: your r briet	s froi manu fly ex	m the uscrip oplain	mar ot), oi why	nusc r elal	cript (include quotes in quotation marks "like this" to aborate on this item by providing additional

Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript

include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or
elaborate on this item by providing additional information not in the ms, or briefly explain why the item is
not applicable/relevant for your study

We do not include this information in the manuscript. The full protocol
can be assessed by contacting Dr. Mary Greaney
(mary_greaney@dfci.harvard.edu), who is the corresponding author. Study
protocols are stored a secure server at the Dana-Farber Caner Institute.

## 25) Sources of funding and other support (such as supply of drugs), role of funders

#### Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This work was supported by NIH grant R01 CA123228 and 1K05 CA124415."	

#### X27) Conflicts of Interest (not a CONSORT item)

#### X27-i) State the relation of the study team towards the system being evaluated


In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

#### Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The authors declare there are no conflicts of interest."	
About the CONSORT EHEALTH checklist	
About the Consolt Energin thecking	
As a result of using this checklist, did you make changes in your	r manuscrint? *
	i manuscript:
o yes, major changes	
<ul><li>yes, minor changes</li></ul>	
o no	
What were the most important changes you made as a result of t	using this checklist?
Additional detail.	
Llaw much time did you around an acing through the about list IN	CLUDING making abangsa in
How much time did you spend on going through the checklist IN your manuscript *	CLUDING making changes in
7-10 hours.	
7-10 Hours.	
As a result of using this checklist, do you think your manuscript	has improved? *
• yes	·
o no	
Other:	
Would you like to become involved in the CONSORT EHEALTH gr	roup?
This would involve for example becoming involved in participating in a v	
"Explanation and Elaboration" document	
o yes	
no	
Other:	



#### STOP - Save this form as PDF before you click submit

To generate a

record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Submit

Powered by Google Docs

Report Abuse - Terms of Service - Additional Terms

39 of 39